Eye drops able to reverse dilation
Vitaris announced the commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States. RYZUMVI is now the only commercially available FDA-approved eye drop to reverse dilation in the United States. The onset of action of RYZUMVI generally occurs in 30 minutes. In the MIRA-2 and MIRA-3 clinical trials, at 90 minutes after administration, 49% and 58% of patients administered 2 drops of RYZUMVI returned to ≤ 0.2 mm of baseline pupil diameter compared to 7% and 6% of patients administered placebo, respectively. 

See: https://newsroom.viatris.com/2024-04-01-Viatris-Announces-the-Launch-of-RYZUMVl-TM-Phentolamine-Ophthalmic-Solution-0-75-in-the-United-States 

Transition lenses with UVA, UVB, and blue violet light filtering
Transitions Optical has released the Transitions Gen S lens. The Transitions Gen S lens is fully clear indoors and can quickly darken when outdoors, according to the company, reaching category three levels of darkness in 25 seconds and fading back in less than two minutes. The Transitions Gen S lenses are available in 8 colors, including the new color ruby. The lenses are also capable of blocking 100 percent UVA & UVB rays and filtering up to 32 percent of blue violet light in the clear state and up to 85 percent when activated.

See: TransitionsPRO.com/GenS.

Virtual reality visual field
Virtual Vision Health, an ophthalmic virtual reality visual field company, unveiled new testing features to its Virtual Eye Pro headset. One of the new features, Live Eye Monitoring and Streaming, uses infrared cameras and lights to track gaze and improve exam reliability; the system alerts the patient if their gaze is not fixated on the focus point, freeing staff to perform other tasks in clinic while testing is conducted. Additionally, it enables pupillometry and improved ptosis and dermatochalasis testing. The second feature, Pupillography, measures and records pupillary responses. It is used to study, identify, and treat the underlying stimuli that cause certain pupillary reactions.

See: https://virtualvision.health/